Results from clinical trials evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System continue to show this advanced transcatheter aortic valve implantation (TAVI) therapy delivers...

First Guidewire Designed Specifically for TAVI/R Now Sized for Smaller Ventricles Boston Scientific (NYSE: BSX) announces CE Mark and FDA clearance for the Safari2™ Pre-Shaped Guidewire, a new...

Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and Safety A new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System...

New data for the Lotus™ Valve System announced at PCR London Valves 30-Day outcomes for the 250 patients enrolled in REPRISE II Extended Cohort trial were presented by Prof Ian Meredith at PCR...

Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...